An open-label, multicenter, multinational study of Lacosamide as first add-on anti-epileptic drug (AED) treatment in subjects with partial-onset seizures

HS 2009-7100
Seizures, Brain & Nerve, Epilepsy
Neal Hermanowicz, MD
The purpose of this study is to measure the seizure freedom among subjects who add oral lacosamide (LCM) as a first add-on anti-epileptic drug (AED), twice a day, to their current anti-epileptic drug(s).
Males and females aged 17 to 65 who are diagnosed with epilepsy classified as partial-onset seizures. Subjects are being asked to participate in this clinical research study because they continue to have seizures despite current treatment.
Study participation will include up to 9 visits, 1 to 2 hours long each, over approximately 34 weeks.
Seizures may improve while in the study, but this cannot be guaranteed.

$200

Lacosamide
Shari Niswonger, RN, Department of Neurology
949-824-8116